ABUS Stock Summary and Trading Ideas (Arbutus Biopharma | NASDAQ:ABUS)

Arbutus Biopharma Corp is a biopharmaceutical company. The company discovers, develops, and commercializes cures for patients suffering from Hepatitis B infection. It is focused on developing a portfolio of drug candidates with multiple mechanisms of action and is also involved in licensing Lipid nanoparticle technology.

Arbutus Biopharma trades on the NASDAQ stock market under the symbol ABUS.

As of June 2, 2023, ABUS stock price climbed to $2.58 with 486,892 million shares trading.

ABUS has a beta of 0.51, meaning it tends to be less sensitive to market movements. ABUS has a correlation of 0.05 to the broad based SPY ETF.

ABUS has a market cap of $428.62 million. This is considered a Small Cap stock.

Last quarter Arbutus Biopharma reported $7 million in Revenue and -$.10 earnings per share. This beat revenue expectation by $657,000 and exceeded earnings estimates by $.04.

In the last 3 years, ABUS stock traded as high as $9.02 and as low as $1.60.

The top ETF exchange traded funds that ABUS belongs to (by Net Assets): VTI, IWM, VXF, IBB, IWN.

ABUS has underperformed the market in the last year with a price return of -2.3% while the SPY ETF gained +4.1%. ABUS has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -8.2% and +0.4%, respectively, while the SPY returned +7.9% and +2.2%, respectively.

ABUS support price is $2.44 and resistance is $2.56 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ABUS stock will trade within this expected range on the day.